Belite Bio, Inc (BLTE:NASDAQ) closed at $162.56 on November 16, 2026, down 1.09% on the day. The stock trades 18.7% below its 52-week high of $200.00 and 53.5% above its 52-week low of $105.88. Over the past year, it gained 32.0%. Belite Bio, Inc is part of the Health Care sector.
In 252 trading sessions since November 14, 2025, BLTE closed higher on 120 days (48%). Its best day was September 4, 2026 (+13.16%) and its worst was November 20, 2025 (-9.29%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Find more stocks like BLTE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.